Affordable Access

deepdyve-link deepdyve-link
Publisher Website

A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity.

Authors
Type
Published Article
Journal
Circulation
1524-4539
Publisher
Ovid Technologies Wolters Kluwer -American Heart Association
Publication Date
Volume
127
Issue
1
Pages
74–85
Identifiers
DOI: 10.1161/CIRCULATIONAHA.112.091215
PMID: 23186644
Source
Medline
License
Unknown

Abstract

Weight-neutral treatment with a glucagon-like peptide-1 analog activates several cardioprotective pathways, prevents HFD-induced insulin resistance and inflammation, reduces monocyte vascular adhesion, and improves cardiac function in vivo by activating AMP-activated protein kinase. These data support a role for glucagon-like peptide-1 analogs in limiting the cardiovascular risks of obesity.

Statistics

Seen <100 times